Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

3.31USD
16 Feb 2018
Change (% chg)

$0.09 (+2.64%)
Prev Close
$3.22
Open
$3.22
Day's High
$3.33
Day's Low
$3.21
Volume
61,225
Avg. Vol
156,139
52-wk High
$5.71
52-wk Low
$1.12

Chart for

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 2.19
Market Cap(Mil.): $142.32
Shares Outstanding(Mil.): 43.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib

* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA

Feb 07 2018

BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL

Jan 26 2018

BRIEF-Verastem Announces Increased Hercules Debt Facility

* VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC

Jan 04 2018

BRIEF-Verastem Announces Pricing Of Public Offering Of Common Stock

* VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 15 2017

BRIEF-Verastem Announces Public Offering Of Common Stock

* VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

Dec 14 2017

BRIEF-‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​

* ‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​

Dec 10 2017

BRIEF-Verastem reports Q3 loss per share of $0.61

* Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​

* Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA

Oct 31 2017

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

Oct 17 2017

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.

Sep 06 2017

Earnings vs. Estimates